Mesoblast (MESO) Non-Current Deffered Revenue (2018 - 2025)
Mesoblast's (MESO) quarterly Non-Current Deffered Revenue came in at $2.5 million in Q4 2025, little changed year-on-year from $2.5 million in Q4 2024, and little changed quarter-over-quarter from $2.5 million in Q2 2025.
Mesoblast (MESO) Non-Current Deffered Revenue (2018 - 2025) Analysis & Trends
Mesoblast has disclosed Non-Current Deffered Revenue across 8 years of filings, most recently posting $2.5 million for Q4 2025.
- Non-Current Deffered Revenue for Q4 2025 came in at $2.5 million, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.5 million (changed 0.0% YoY), and the FY2025 annual result was $2.5 million, changed 0.0% from the prior year.
- Non-Current Deffered Revenue came in at $2.5 million for Q4 2025 at Mesoblast, roughly flat from $2.5 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $2.5 million in Q1 2021 to a low of $2.5 million in Q1 2021.
- The 5-year median for Non-Current Deffered Revenue is $2.5 million (2021), against an average of $2.5 million.
- Peak annual rise in Non-Current Deffered Revenue reached 0.0% in 2021, while the deepest fall reached 0.0% in 2021.
- Mesoblast's Non-Current Deffered Revenue stood at $2.5 million in 2021, then changed by 0.0% to $2.5 million in 2022, then changed by 0.0% to $2.5 million in 2023, then changed by 0.0% to $2.5 million in 2024, then changed by 0.0% to $2.5 million in 2025.
- The last three Non-Current Deffered Revenue figures came in at $2.5 million (Q4 2025), $2.5 million (Q2 2025), and $2.5 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Mesoblast | 21.68 Bn | 21.55 Bn | - | 2.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.50 Mn |
| Jun 30, 2025 | 2.50 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Jun 30, 2024 | 2.50 Mn |
| Dec 31, 2023 | 2.50 Mn |
| Jun 30, 2023 | 2.50 Mn |
| Mar 31, 2023 | 2.50 Mn |
| Dec 31, 2022 | 2.50 Mn |
| Sep 30, 2022 | 2.50 Mn |
| Jun 30, 2022 | 2.50 Mn |
| Mar 31, 2022 | 2.50 Mn |
| Dec 31, 2021 | 2.50 Mn |
| Sep 30, 2021 | 2.50 Mn |
| Jun 30, 2021 | 2.50 Mn |
| Mar 31, 2021 | 2.50 Mn |
| Dec 31, 2020 | 2.50 Mn |
| Sep 30, 2020 | 2.50 Mn |
| Jun 30, 2020 | 2.50 Mn |
| Mar 31, 2020 | 2.50 Mn |
| Dec 31, 2019 | 10.00 Mn |